Gapping up
In reaction to earnings/guidance:
- ORGO +31.5% (guides Q4 revs well above consensus), APYX +24.7% (guides Q4 revs above consensus), ETH +9.4% (guides DecQ EPS above consensus), CAJ +4.4%, APHA +4.3%, SIG +2.5%, TSM +2.3%, FRC +1.4%, DAL +1.4%, BLK +1.3%
M&A news:
- AVAV +6.7% (to acquire Arcturus UAV for $405 mln)
Select semiconductor related names showing strength following TSM earnings/CAPEX outlook:
- AMAT +3.5%, KLAC +3.4%, LRCX +2.7%, TER +2.5%, MKSI +0.9%, SMH +0.8%
Other news:
- NK +32.7% (reports positive interim data on survival rates in metastatic pancreatic cancer trials)
- ORGO +32.2% (enrolls first patient in pivotal phase 3 clinical trial of RMAT-designated ReNu for knee osteoarthritis)
- PFSW +29.2% (reports Q4 orders fulfilled increased 88%)
- BCYC +10.8% (Bicycle Toxin Conjugates targeting oncological indications, as well as its novel, fully synthetic Bicycle tumor-targeted immune cell agonists)
- CEMI +10.2% (announces the CE mark for the DPP SARS-CoV-2 Antigen and IgM/IgG test systems, providing regulatory approval to register and market both test systems in the European Union and other geographies that accept the CE mark)
- ORTX +8.5% (FDA has granted RMAT designation to OTL-200 for the treatment of early-onset metachromatic leukodystrophy)
- ALDX +5.2% (prices offering of 6,842,106 shares of its common stock at $9.50 per share)
- PGEN +5.1% (presents pipeline updates)
- APA +3.9% (Apache and Total (TOT) announced an oil discovery at the Keskesi East-1 exploration well in Block 58 offshore Suriname)
- SIGA +3.6% (Canada to purchase $33 mln of oral TPOXX)
- XL +3.5% (files for offering of common stock and warrants )
- NVTA +3.2% (announces the launch of a new project with Bristol Myers Squibb (BMY), Janssen Research & Development (JNJ), Novartis (NVS) and Genentech, a member of the Roche (RHHBY) Group, to develop a standardized panel for MRD detection in patients with AML)
- TMST +3.1% (to increase SBQ prices by $40/ton)
- PRVB +2.7% (prices offering of 6.25 mln shares of common stock at $16.00 per share)
- VRNA +2.5% (completes enrollment in pilot study of pMDI Ensifentrine in U.S. patients hospitalized with COVID-19)
- KLDO +2% (announces positive interim results of controlled study of KB109 in patients with mild-to-moderate COVID-19)
- JNJ +1.7% (says single-dose COVID-19 vaccine provided immune response that lasted for at least 71 days)
- NEM +1.2% (approved a share repurchase program for up to $1.0 billion of common equity, to be completed over the next 18 months)
Analyst comments:
- SITC +3.3% (upgraded to Overweight from Neutral at Piper Sandler)
- INTC +2.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley, among others)
- CMG +1.4% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- ODFL +1.4% (upgraded to Neutral from Sell at Goldman)
- HHR +1.2% (upgraded to Neutral from Underperform at BofA Securities)
- PPG +1% (upgraded to Buy from Hold at Berenberg)